Pediatric Pulmonology Flashcards
Infant respiratory distress syndrome
Formerly known as Hyaline
Membrane Disease
○ Most common cause of respiratory
distress in the preterm infant
○ More likely if born before 37 weeks
gestation
Cause of IRDS:
- Prematurity of the lungs
- Deficiency in pulmonary
surfactant
Surfactant
- Mixture of phospholipids & proteins synthesized & excreted
by Alveolar type II cells of the alveolus. - Decreases surface tension of the alveolar sac.
What cells make surfactant?
Alveolar type II
Surfactant deficiency =
high surface tension, alveolar collapse (atelectasis)
= ↑ pulmonary dead space
* Inflammation, pulmonary edema, hypoxia, poor oxygenation,
↑ respiratory effort, & eventually respiratory failure
Lung Development
- Surfactant production begins ~20 weeks
- ~24 weeks alveolar sacs are present (survival possible)
- Overall survival rate ~50%
- ~30% survive without severe morbidity
Best prevention of IRDS
Prevention of preterm birth
Alveoli collapse causes:
- Decreased gas exchange
- Decreased lung compliance &
functional residual capacity
Decreased gas exchange leads to:
○ Acidosis (Respiratory & metabolic)
○ Pulmonary vasoconstriction
○ Endothelial & epithelial breakdown
○ Leads to protein rich exudate
○ Hyaline membranes (accumulation of dead
cells and proteins that line the alveoli)
Decreased lung compliance &
functional residual capacity
○ ↑ dead space
○ V/Q (ventilation/perfusion)
mismatch & Hypoventilation
○ Right-to-left Cardiac shunt
○ Hypoxemia & hypercarbia
○ Respiratory acidosis
Clinical Presentation of IRDS
○ Respiratory distress (min.
to hours after birth)
○ Dyspnea
○ Retractions
○ Hypoxia
○ Grunting
○ Cyanosis
Diagnosis of IRDS
○ Chest X-ray
■ Diffuse signs of both interstitial
& alveolar congestion
■ Air bronchograms
■ Interstitial reticular pattern
■ “ground glass appearance”
○ ABG
o Blood cultures
Treatment of IRDS
○ Intratracheal surfactant administration
○ Supplementary oxygen as needed
○ Mechanical ventilation as needed
Intratracheal surfactant administration
○ Requires intubation
○ Best if followed by rapid extubation and switch to CPAP
○ Good evidence for CPAP immediately after delivery of premature
infant (keeps the alveoli open at the end of expiration)
○ Or MIST (minimally invasive surfactant therapy) just uses thin
catheter into the trachea.
What would glucocorticoids do in preventing IRDS?
○ Glucocorticoids administered to mother
○ Betamethasone or dexamethasone given to
mother if delivery necessary between 24-34
weeks
○ Stimulates maturation of the baby’s lung tissue & surfactant release
Exogenous Surfactant
○ Exogenous aerosol via endotracheal
tube
○ Used if pt unresponsive to CPAP or
HFNC
○ Natural & Synthetic Surfactant options
○ Natural may be superior
○ Poractant Alfa
○ Calfactant
○ Beractant
Complications of IRDS
● Respiratory Acidosis
● Metabolic Acidosis
● Pulmonary Edema
● Infection
● Air Leak - Pneumothorax,
Pneumomediastinum
● Necrotizing Enterocolitis
Bronchopulmonary Dysplasia
Formerly called Chronic Lung Disease of Infancy
● Chronic pulmonary condition
● Sequelae of neonatal acute respiratory
distress, regardless of cause
● Typically caused by prolonged
mechanical ventilation
Bronchopulmonary Dysplasia pathophysiology
○ Poorly understood
○ Supplemental O2 w/ premature
lungs
○ Barotrauma, Oxidative Stress
○ Premature lungs more
susceptible to inflammation
caused by mechanical
ventilation
“Considered present when there is prolonged need for
supplemental oxygen in premature infants after 28 days of
age… and who do not have other conditions requiring oxygen”
Bronchopulmonary dysplasia